{"slideshow_credits": null, "snippet": "States should not move to limit access to biosimilar drugs before the F.D.A. has issued final safety guidelines.", "abstract": "Editorial cites case of biotechnology companies Amgen and Genentech, who are both lobbying state legislatures to limit competition to their biological drugs that will be losing patent protection; cautions state lawmakers not to limit access to generic versions of their drugs until Federal Drug and Administration issues final safety guidelines.", "section_name": "Opinion", "print_page": "18", "document_type": "article", "byline": [], "web_url": "http://www.nytimes.com/2013/02/09/opinion/improper-efforts-to-limit-competitive-drugs.html", "lead_paragraph": "States should not move to limit access to biosimilar drugs before the F.D.A. has issued final safety guidelines.", "headline": {"seo": "Improper Efforts to Limit Competitive Drugs", "main": "Improper Efforts to Limit Competitive Drugs", "print_headline": "Improper Efforts to Limit Competitive Drugs", "content_kicker": "Editorial", "kicker": "Editorial"}, "_id": "51208010cf28d009de0003d8", "word_count": "334", "multimedia": [], "pub_date": "2013-02-09T00:00:00Z", "source": "The New York Times", "news_desk": "Editorial", "keywords": [{"value": "Genentech Inc", "name": "organizations", "is_major": "Y", "rank": "1"}, {"value": "Amgen Inc", "name": "organizations", "is_major": "Y", "rank": "2"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Biotechnology", "name": "subject", "is_major": "N", "rank": "4"}, {"value": "Lobbying and Lobbyists", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Generic Brands and Products", "name": "subject", "is_major": "Y", "rank": "6"}, {"value": "Food and Drug Administration", "name": "organizations", "is_major": "Y", "rank": "7"}, {"value": "Editorials", "name": "subject", "is_major": "Y", "rank": "8"}], "blog": [], "subsection_name": null, "type_of_material": "Editorial"}